The estimated Net Worth of Bryant Fong is at least 5.7 百万$ dollars as of 31 August 2016. Mr. Fong owns over 1,500 units of Adma Biologics Inc stock worth over 25,365$ and over the last 10 years he sold ADMA stock worth over 5,546,886$. In addition, he makes 125,805$ as Independent Director at Adma Biologics Inc.
Sign up
Mr. Fong ADMA stock SEC Form 4 insiders trading
Bryant has made over 2 trades of the Adma Biologics Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he sold 1,433,304 units of ADMA stock worth 5,546,886$ on 22 August 2023.
The largest trade he's ever made was selling 1,433,304 units of Adma Biologics Inc stock on 22 August 2023 worth over 5,546,886$. On average, Bryant trades about 65,218 units every 116 days since 2014. As of 31 August 2016 he still owns at least 1,500 units of Adma Biologics Inc stock.
You can see the complete history of Mr. Fong stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Bryant Fong biography
Bryant E. Fong serves as Independent Director of the Company. Mr. Fong, who became a director of the Company in May 2012 and is currently a member of the Company’s Audit Committee, Compensation Committee and Governance and Nominations Committee, has over 25 years of experience in the life sciences industry. Mr. Fong is a founding Managing Director and General Partner at Biomark Capital Fund, a life sciences private equity firm formed in 2013 (“Biomark Capital”). Prior to Biomark Capital, Mr. Fong was a Managing Director and General Partner of Burrill & Company, where he spent almost 16 years investing in and managing investments in private and public companies in the biotechnology industry. Some of Mr. Fong’s most notable investments include Pharmasset (VRUS), Novadaq Technologies (NVDQ), Galapagos (GLPG), Ceptaris Therapeutics, Ferrokin Biosciences, WaveTec Vision and JHL Biotech. Prior to joining Burrill & Company, Mr. Fong held positions as a research scientist with two early stage biotechnology companies located in the San Francisco Bay area. Mr. Fong currently serves on the boards of directors of a number of private life science companies. Mr. Fong earned his B.S. with honors in Molecular and Cell Biology-Biochemistry from the University of California, Berkeley. He was nominated by Biomark Capital to serve on the Board because of his extensive experience in the biotechnology industry.
What is the salary of Bryant Fong?
As the Independent Director of Adma Biologics Inc, the total compensation of Bryant Fong at Adma Biologics Inc is 125,805$. There are 8 executives at Adma Biologics Inc getting paid more, with Adam Grossman having the highest compensation of 1,702,020$.
How old is Bryant Fong?
Bryant Fong is 47, he's been the Independent Director of Adma Biologics Inc since 2012. There are 9 older and 2 younger executives at Adma Biologics Inc. The oldest executive at Adma Biologics Inc is Dr. James Mond, 74, who is the Exec. VP, Chief Scientific Officer & Chief Medical Officer.
What's Bryant Fong's mailing address?
Bryant's mailing address filed with the SEC is 2940 N State Hwy 360 Service Rd E #400, Grand Prairie, TX 75050, USA.
Insiders trading at Adma Biologics Inc
Over the last 11 years, insiders at Adma Biologics Inc have traded over 43,950,328$ worth of Adma Biologics Inc stock and bought 17,510,201 units worth 56,736,742$ . The most active insiders traders include Advisors Llcperceptive Life...、Ag Biotest Pharmaceuticals ...、Divestiture Trust Biotest. On average, Adma Biologics Inc executives and independent directors trade stock every 34 days with the average trade being worth of 7,366,858$. The most recent stock trade was executed by Lawrence P. Guiheen on 9 September 2024, trading 9,000 units of ADMA stock currently worth 97,200$.
What does Adma Biologics Inc do?
adma is a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of primary immune deficiency disease (pidd) and certain infectious diseases. adma's mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases. the target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease, or who may be immune-compromised for medical reasons. adma’s lead product candidate, ri-002, has completed a phase iii clinical trial in patients with pidd and has met the primary endpoint. a bla for ri-002 was accepted by the fda on september 18, 2015. the company has received u.s. patent 9,107,906. for more information, please visit the company's website at www.admabiologics.com.
What does Adma Biologics Inc's logo look like?
Complete history of Mr. Fong stock trades at Adma Biologics Inc、Neos Therapeutics Inc
Adma Biologics Inc executives and stock owners
Adma Biologics Inc executives and other stock owners filed with the SEC include:
-
Adam Grossman,
President, Chief Executive Officer, Co-Founder, Director -
James Mond,
Executive Vice President, Chief Scientific Officer, Chief Medical Officer -
Adam S. Grossman,
Co-Founder, Pres, CEO & Director -
Brian Lenz,
Chief Financial Officer, Executive Vice President -
Dr. James Mond,
Exec. VP, Chief Scientific Officer & Chief Medical Officer -
Brian Lenz CPA, CPA,
Exec. VP, CFO & GM of ADMA BioCenters -
Jerrold Grossman,
Vice Chairman of the Board, Co-Founder -
Steven Elms,
Independent Chairman of the Board -
Bryant Fong,
Independent Director -
Lawrence Guiheen,
Independent Director -
Dr. Jerrold B. Grossman D.P.S., Ph.D.,
Co-Founder & Vice Chairman -
Dr. Jerrold B. Grossman Ph.D., D.P.S.,
Co-Founder & Vice Chairman -
Martha Demski,
Independent Director -
Cyndi Tolman,
Sr. VP of Plasma Services -
Neal C. Fitzpatrick,
VP of Sales -
Michael Goldstein,
Sr. Director & Gen. Counsel -
Dr. Gene A. Wetzstein BCOP, Pharm.D.,
Exec. Director & Head of Scientific Engagement -
Drew Pantello,
VP of Marketing & Corp. Devel. -
Michael Least,
VP of Sales & Commercial Operations -
Kaitlin Kestenberg,
VP of Compliance, Project Management & Clinical Operations -
Skyler Bloom,
Director of Investor Relations & Corp. Strategy -
Kim Tripodo,
Exec. Director & Head of Human Resource and Admin. Operations -
Eric I Richman,
Director -
Dov A Md Goldstein,
Director -
Ag Biotest Pharmaceuticals ...,
-
Young Kwon,
-
Alison Cecily Finger,
-
Divestiture Trust Biotest,
10% owner -
Steve Elms,
-
Advisors Llcperceptive Life...,
-
Brad L. Tade,
CFO and Treasurer -
Kaitlin M. Kestenberg Messina,
COO and SVP, Compliance